ABSTRACT
The immune system plays a critical role determining the outcomes in transplanted multiple myeloma patients, since enhanced lymphocyte recovery results in improved survival. Since mobilization regimens influence the cellular subsets collected and infused for transplant, these regimens may determine immune recovery following transplant. We hypothesized that a mobilized stem cell product harboring an increased number of lymphocytes would enhance immune recovery following autologous stem cell infusion, increase lymphocyte recovery, and improve clinical outcomes. We designed a phase I immune mobilization trial using IL-2 and growth factors to increase the number of lymphocytes within the stem cell product. This regimen efficiently mobilized CD34 + progenitor cells (median: 3.6 x 10 6 cells/kg; range 1.9-6.6 x 10 6 cells/kg) and improved the immune properties of the mobilized stem cells, including an increase in CD8 + T cells expressing an NK activating receptor called NKG2D (P< 0.004), cells that are extremely potent at killing myeloma cells using non-MHC-I restricted and TCR-independent mechanisms. Novel mobilization techniques can improve the mobilized graft and may improve clinical outcomes in myeloma patients.
INTRODUCTION
Multiple myeloma (MM) is an incurable disease with a median survival of 3 to 7 years after diagnosis. (1) Autologous stem cell transplant improves survival but the immunologic mechanisms accounting for this improvement are unknown.
The immune system plays an integral part in the survival of myeloma patients. For example, myeloma patients demonstrating a higher absolute lymphocyte count on day 15 (ALC15) following transplantation experience an improved survival. (2) (3) (4) (5) (6) (7) (8) In addition, the number of lymphocytes infused as part of the stem cell product directly impacts the ALC15. (2, 9) The cellular subsets of the stem cell product that are responsible for these benefits are unknown. Therefore, we hypothesized that a mobilized stem cell product containing an increased number of lymphocytes, enriched for tumor-destroying cells, would improve immune recovery following autologous stem cell infusion, increase the ALC 15, and may improve clinical outcomes.
We previously evaluated immune mobilization of hematopoietic progenitor cells (HPC) in a mouse model T cells within the collected cellular product in patients mobilized on this clinical trial using IL-2 and growth factors. We will describe the clinical and laboratory results from the myeloma patients treated on a clinical trial evaluating immune mobilization of autologous peripheral blood stem cells (PBSC).
METHODS

Immune mobilization treatment regimen
We designed an immune mobilization trial examining dose-escalated IL-2 (Prometheus Therapeutics and Diagnostics, San Diego, CA) in combination with GM-CSF (Bayer Pharmaceuticals, Pittsburgh PA) and rhG-CSF (Amgen, Thousand Oaks, CA), as previously described. Blood samples were obtained from patients prior to starting therapy, on Day 7 of mobilization (after 7 days of IL-2) and on Day 11 of mobilization (after 11 days of IL-2 and 5 days of growth factor support). Patients who received mobilization with rhG-CSF alone served as our control group. Bone marrow aspirates from patients were obtained before initiating therapy or when indicated during their treatment course. Normal marrow was obtained from volunteer patients. All patients signed an IRB-approved consent prior to donations.
Cell lines
A human myeloma cell line (RPMI8226) and a human leukemia cell line (K562) were obtained from American Type Culture Collection (Rockville, MD). Cell lines were cultured in RPMI 1640 medium (Cellgro, Herndon, VA) and supplemented with 10% heat inactivated fetal bovine serum (FBS from Gemini Bio-products, West Sacramento, CA), 2mM L-Glutamine, 100U/ml Penicillin, 100ug/ml Streptomycin (Invitrogen Corp., Carlsbad, CA).
Flow cytometry analyses
Cell surface phenotype of peripheral blood mononuclear cells (PBMC) was examined using flow cytometry with fluorochrome-conjugated antibodies directed against T lymphocyte markers (CD3, CD4, CD8), an NK cell marker (CD56), the IL-2 receptor (CD25), and an NK cell activating receptor (NKG2D). Phenotypes were analyzed using FACScan or FACSCanto (Becton Dickinson, San Jose, CA) using a standard lymphocyte gate and recorded as percent of positive cells within the specified population. Data were analyzed using Cell quest (Becton Dickinson, San Jose, CA) and FlowJo software (Tri star INC., Chatsworth, CA).
Cytotoxicity assays
We used two methods to test cytotoxicity and to determine the mechanism of tumor cell killing. A standard chromium release assay was performed at three effector to target ratios (E:T : 100:1, 20:1, and 4:1) as previously described. (15)A myeloma cell line (RPMI8226), a An alternative cytotoxicity assay, a CFSE-based assay, was used when patients' effector cell numbers were limited. RPMI 8226 myeloma cell lines or K562 CML cell lines were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) conjugated to FITC, at 5µM for 6 minutes at 4 o C in the dark. CFSE-based cytotoxicity assay was performed using purified CD8 + T cells as effector cells and CFSE-labeled cell lines as targets at a E:T ratio of 50:1 and 100:1 at 37C for 5 hours. Monensin, a Na + /H + antiporter, was added for the last 4 hours of culture to block intracellular protein transport. After 5 hours of incubation, cells were labeled with anti-NKG2D (APC) and Anti-CD8 (APC-Cy7) and anti-CD107a (PE), and Propidium Iodide (PI) to identify dead cells, and analyzed by flow cytometry. Dead cells were identified as those doubly labeled with CFSE-FITC and PI. + T cells were used as effector cells in vitro. Briefly, PBMC were cultured in serum-free AIM V medium (Invitrogen Corp., Carlsbad, CA) for 2 hours at 37 0 C and 5% CO 2 . The lymphocyte-enriched cell population was removed and cultured in serum-free AIM V media supplemented with IL-2 (1000IU/ml; Prometheus Therapeutics and Diagnostics, San Diego, CA) and OKT3 (500ng/ml; Ortho Biotech Products, Raritan, NJ) every other day for 7 days. Cell viability was determined by Trypan Blue, using either a hemocytometer or an automated cell counter (Cellometer AutoT4 PLUS, Nexelom Biosciences LLC Lawrence, MA). Cell expansion and phenotype was determined using flow cytometry (FACScan or FACSCanto, Becton Dickinson, San Jose, CA) and percent positive cells within a lymphocyte gate were recorded. Cryopreserved PBMC from myeloma patients were isolated, as previously described. (15)The PBMC were then expanded for 7 days using IL-2 (1000IU/ml) and OKT3 (500ng/ml), a process that enriches for NKG2D + CD8 + T cells. First, CD8 + T cells were isolated using a magnet-activated automated cell separation system (AutoMACS, Miltenyi Biotec AG, Bergisch Gladbach, Germany) as per manufacturer's protocol. Cells were labeled with 40µl of CD8 + sorting microbeads at 4 o C for 15 minutes. Cells were then washed with 4ml of staining buffer and resuspended in 500 µl MACS buffer, and transferred to a 15ml tube. After magnetic separation, purified CD8 + cells were labeled with anti-NKG2D (APC) and Anti-CD8 (APC-Cy7) and anti-CD107a (PE) in presence of IL-2 at 50U/ml. 
Ex vivo
Statistical analyses
Statistical analyses for differences observed in each experiment were determined using the Student's t-test at the 95% confidence interval. Graph Pad PRISM 5 statistical software, (La Jola, CA) or Microsoft Excel, (Redmond WA) was used.
RESULTS
Summary of clinical results
We accrued eleven multiple myeloma patients to this phase I clinical trial. These clinical results were previously published. (11)Ten patients completed the full course of treatment. The median number of CD34 + cells/kg collected was 3.6 x 10 6 cells/kg (range of 1.9 -6.6 x 10 6 CD34 + cells/kg). All patients engrafted after transplant without delay. The median number of days for neutrophil engraftment was 12.3 days (range: 9-14 days), and 10.5 days for platelet recovery (range: 0-17 days). There were no treatment-related mortalities and grade 2 (moderate) toxicities or greater were minimal and included: back pain (n=2 patients), fever (n=2 patients), nausea (n=1 patient), chills (n=1 patient), anorexia (n=1 patient), diarrhea (n=1 patient), fluid retention (n=1 patient), and vascular leak (n=1 patient).
Immune mobilization results in ample CD34 + cells and effector cell numbers
The immune mobilization regimen markedly increased the number of NKG2D + cytotoxic T cells that demonstrated enhanced lytic ability against human tumor cells. There was increased lysis of the RPMI 8226 myeloma cells by patients' cytotoxic T cells after 7 days of IL-2 treatment (P<0.01) and this lysis was sustained at Day 11 or the day of collection (P < 0.05). (Figure 4a ) Patients' cytotoxic T cells also effectively lysed K562 cells, a CML 
DISCUSSION
We hypothesized that a mobilized stem cell product containing an increased number of lymphocytes, would improve immune recovery following autologous stem cell infusion, increase the ALC 15, and may improve clinical outcomes. Our data demonstrate that CD8 + T lymphocytes upregulate surface expression of NKG2D in vivo during immune mobilization, rendering highly effective lymphocytes, especially, NKG2D + T lymphocytes, which may improve immune recovery, increase the ALC15 and possibly improve clinical outcomes in myeloma patients.
Immune mobilization is a novel form of therapy. We postulate that the increased number and function of the NKG2D + CD8
+ T cells within the autologous graft may offer a clinical benefit by aggressively eliminating residual malignant cells in vivo. Our studies introduce a successful method of NKG2D upregulation on patients' effector cells that demonstrate an attractive model for targeted tumor immunotherapy in myeloma patients. We demonstrate a clinically applicable approach with minimal toxicity and no detrimental effect on CD34 + progenitor cell mobilization. The results of our novel immune mobilization regimen indicate a promising future for the development of a targeted therapy against myeloma that may improve clinical outcomes.
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